Belite Bio moves to Nasdaq Global Select Market

SAN DIEGO - Belite Bio, Inc. (NASDAQ:BLTE) announced it received approval from Nasdaq to move its securities listing from the Nasdaq Capital Market to the Nasdaq Global Select Market. The transfer of trading began today under the same ticker symbol, BLTE. The Nasdaq Global Select Market is the top tier of Nasdaq markets. This uplisting demonstrates the company's adherence to Nasdaq's financial and liquidity requirements.

Belite Bio is a clinical-stage biotech company specializing in treatments for degenerative retinal diseases. Dr. Tom Lin, Chairman and CEO of Belite Bio, stated that the uplisting represents the company's continued focus on financial discipline and successful business execution. The company's lead drug candidate, tinlarebant, is an oral medication designed to minimize the buildup of retinoid toxins in the eye.

Belite Bio completed a Phase 3 clinical trial (DRAGON) for tinlarebant in individuals with Stargardt disease type 1, which met its primary objective. The drug is now being assessed in a Phase 2/3 trial (DRAGON II) for Stargardt disease type 1 and a Phase 3 trial (PHOENIX) for geographic atrophy. Investors interested in clinical-stage biotech firms can use InvestingPro, a service that provides in-depth financial data, Fair Value analysis, and expert evaluations, including peer comparisons.

Belite Bio is dedicated to developing treatments for degenerative retinal conditions such as Stargardt disease type 1 and geographic atrophy, as well as specific metabolic disorders.